daunorubicin and cytarabine

Details

Files
Generic Name:
daunorubicin and cytarabine
Project Status:
Complete
Therapeutic Area:
Acute myeloid leukemia
Manufacturer:
Jazz Pharmaceuticals Canada Inc.
Brand Name:
Vyxeos
Project Line:
Reimbursement Review
Project Number:
PC0237-000
Tumour Type:
Leukemia
NOC Status at Filing:
Pre NOC
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openDecember 17, 2020
Call for patient/clinician input closedFebruary 12, 2021
Clarification:

- Patient input submission received from The Leukemia & Lymphoma Society of Canada

Submission receivedJanuary 22, 2021
Submission acceptedFebruary 05, 2021
Review initiatedFebruary 08, 2021
Draft CADTH review report(s) provided to sponsor for commentApril 23, 2021
Deadline for sponsors commentsMay 04, 2021
CADTH responses on draft review report(s) provided to sponsorMay 31, 2021
Expert committee meeting (initial)June 10, 2021
Draft recommendation issued to sponsorJune 24, 2021
Draft recommendation posted for stakeholder feedbackJuly 08, 2021
End of feedback periodJuly 22, 2021
Final recommendation issued to sponsor and drug plansAugust 6, 2021
Final recommendation postedAugust 24, 2021
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)August 23, 2021
CADTH review report(s) postedOctober 29, 2021